Related Experiment Video
Updated: Jul 15, 2026
Adenoviral Transduction of Naive CD4 T Cells to Study Treg Differentiation
Published on: August 13, 2013
Inhibition of transmethylation down-regulates CD4 T cell activation and curtails development of autoimmunity in a
Brian R Lawson1, Yulia Manenkova, Jasimuddin Ahamed
1Diazyme Laboratories Division, General Atomics, San Diego, CA 92186, USA. blawson@scripps.edu
Abstract:
Transmethylation affects several cellular events, including T cell activation, and blockade of this pathway may curtail inflammatory/autoimmune responses. Here, we demonstrate that transmethylation inhibition by a novel reversible S-adenosyl-l-homocysteine hydrolase inhibitor leads to immunosuppression by reducing phosphorylation of several key proteins involved in TCR signaling, including Akt, Erk1/2, and NF-kappaB. Remarkably, this effect was largely restricted to CD4 T cells and correlated with reduced arginine methylation of Vav1, an essential guanine nucleotide exchange factor in T cell stimulation. Treatment with the transmethylation inhibitor averted, and even ameliorated, the CD4-mediated autoimmune disease, experimental autoimmune encephalomyelitis. The data suggest that transmethylation is required for CD4 T cell activation, and its inhibition may be a novel approach in the treatment of multiple sclerosis, and other CD4-mediated autoimmune diseases.
Insights
Inhibiting transmethylation suppresses T cell activation by reducing key protein phosphorylation. This novel approach shows promise for treating CD4 T cell-mediated autoimmune diseases like multiple sclerosis.
Area of Science:
- Immunology
- Cellular Biology
- Pharmacology
Background:
- Transmethylation is crucial for cellular events, including T cell activation.
- Blocking transmethylation may reduce inflammatory and autoimmune responses.
- S-adenosyl-l-homocysteine hydrolase (SAHase) is a key enzyme in transmethylation.
Purpose of the Study:
- To investigate the effects of a novel SAHase inhibitor on T cell activation and autoimmune responses.
- To determine the role of transmethylation in CD4 T cell signaling and function.
- To evaluate the therapeutic potential of transmethylation inhibition in CD4-mediated autoimmune diseases.
Main Methods:
- Utilized a novel reversible SAHase inhibitor.
- Assessed T cell activation markers and protein phosphorylation (Akt, Erk1/2, NF-kappaB).
- Examined arginine methylation of Vav1 in CD4 T cells.
- Evaluated the inhibitor's efficacy in a mouse model of experimental autoimmune encephalomyelitis (EAE).
Main Results:
- Transmethylation inhibition led to immunosuppression by reducing TCR signaling protein phosphorylation.
- The immunosuppressive effects were primarily observed in CD4 T cells.
- Inhibition correlated with reduced arginine methylation of Vav1.
- Treatment with the SAHase inhibitor ameliorated EAE, a CD4-mediated autoimmune disease.
Conclusions:
- Transmethylation is essential for CD4 T cell activation.
- Inhibition of transmethylation by a novel SAHase inhibitor results in immunosuppression.
- This approach may offer a new therapeutic strategy for multiple sclerosis and other CD4 T cell-mediated autoimmune diseases.
